A. Friedman

958 total citations
25 papers, 743 citations indexed

About

A. Friedman is a scholar working on Rheumatology, Genetics and Immunology. According to data from OpenAlex, A. Friedman has authored 25 papers receiving a total of 743 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Rheumatology, 9 papers in Genetics and 7 papers in Immunology. Recurrent topics in A. Friedman's work include Systemic Lupus Erythematosus Research (11 papers), Rheumatoid Arthritis Research and Therapies (9 papers) and Chronic Lymphocytic Leukemia Research (8 papers). A. Friedman is often cited by papers focused on Systemic Lupus Erythematosus Research (11 papers), Rheumatoid Arthritis Research and Therapies (9 papers) and Chronic Lymphocytic Leukemia Research (8 papers). A. Friedman collaborates with scholars based in United States, United Kingdom and Japan. A. Friedman's co-authors include Gerald McGwin, Graciela S. Alarcón, John D. Reveille, Holly M. Bastian, Jeffrey M. Roseman, Bruce A. Baethge, Barri J. Fessler, Alfred A. Bartolucci, J.M. Moulds and Jeffrey Lisse and has published in prestigious journals such as Journal of the American College of Cardiology, Annals of the Rheumatic Diseases and Lara D. Veeken.

In The Last Decade

A. Friedman

21 papers receiving 723 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A. Friedman United States	9	621	337	137	107	102	25	743
Sandra Navarra Philippines	9	531 0.9×	402 1.2×	126 0.9×	47 0.4×	154 1.5×	22	739
DJ Wallace United States	13	555 0.9×	348 1.0×	49 0.4×	102 1.0×	136 1.3×	24	732
C Dostál Czechia	14	347 0.6×	209 0.6×	103 0.8×	47 0.4×	82 0.8×	37	547
Zhen Qu China	18	240 0.4×	246 0.7×	673 4.9×	172 1.6×	42 0.4×	44	920
Mercedes García Argentina	12	317 0.5×	192 0.6×	38 0.3×	54 0.5×	98 1.0×	39	447
Kerry Gairy United Kingdom	11	249 0.4×	160 0.5×	79 0.6×	32 0.3×	162 1.6×	29	562
Kristina Wiers United States	9	260 0.4×	203 0.6×	165 1.2×	23 0.2×	41 0.4×	10	451
Gladman Dd Canada	14	661 1.1×	388 1.2×	18 0.1×	112 1.0×	53 0.5×	26	762
Melissa Northcott Australia	9	253 0.4×	272 0.8×	26 0.2×	92 0.9×	74 0.7×	13	457
H. S. Goei Thè Netherlands	14	503 0.8×	159 0.5×	22 0.2×	66 0.6×	31 0.3×	29	720

Countries citing papers authored by A. Friedman

Since Specialization

Citations

This map shows the geographic impact of A. Friedman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Friedman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Friedman more than expected).

Fields of papers citing papers by A. Friedman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Friedman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Friedman. The network helps show where A. Friedman may publish in the future.

Co-authorship network of co-authors of A. Friedman

This figure shows the co-authorship network connecting the top 25 collaborators of A. Friedman. A scholar is included among the top collaborators of A. Friedman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Friedman. A. Friedman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Friedman, A., et al.. (2024). THE CASE OF THE INFECTED CORONARY STENT. Journal of the American College of Cardiology. 83(13). 3376–3376.

Jost, Wolfgang H., A. Friedman, Olaf Michel, et al.. (2023). Long-term incobotulinumtoxinA treatment for chronic sialorrhea: efficacy and safety over 64 weeks. Parkinsonism & Related Disorders. 113.

Friedman, A., et al.. (2023). POS1137 PHARMACOKINETICS AND EXPOSURE-RESPONSE RELATIONSHIPS OF UPADACITINIB OR ELSUBRUTINIB ALONE OR IN COMBINATION (ABBV-599) IN SYSTEMIC LUPUS ERYTHEMATOUS. Annals of the Rheumatic Diseases. 82. 896–897. 1 indexed citations

Gaudreau, Marie‐Claude, et al.. (2023). POS1133 TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH UPADACITINIB RESULTS IN THE COORDINATED INHIBITION OF TYPE 1 IFN-RELATED BIOMARKERS: BIOMARKER ANALYSIS OF THE M19-130 (SLEEK) PHASE 2 STUDY. Annals of the Rheumatic Diseases. 82. 894–895. 2 indexed citations

Merrill, Joan T., Yoshiya Tanaka, David D’Cruz, et al.. (2023). OP0139 EFFICACY AND SAFETY OF ABBV-599 HIGH DOSE (ELSUBRUTINIB 60 MG AND UPADACITINIB 30 MG) AND UPADACITINIB MONOTHERAPY FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS: A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL. Annals of the Rheumatic Diseases. 82. 91–92. 6 indexed citations

Winthrop, Kevin, Juan Ignacio Vargas, Edit Drescher, et al.. (2021). POS0508 EVALUATION OF RESPONSE TO PNEUMOCOCCAL VACCINATION IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING UPADACITINIB: RESULTS FROM A PHASE 2 OPEN-LABEL EXTENSION STUDY. Annals of the Rheumatic Diseases. 80. 486–487. 1 indexed citations

Vollenhoven, Ronald van, Tsutomu Takeuchi, Jacob Aelion, et al.. (2021). POS0655 LONG-TERM SAFETY AND EFFICACY OF UPADACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS: 3-YEAR RESULTS FROM THE SELECT-EARLY STUDY. Annals of the Rheumatic Diseases. 80. 568–569. 2 indexed citations

Vollenhoven, Ronald van, Tsutomu Takeuchi, Maureen Rischmueller, et al.. (2020). THU0217 UPADACITINIB MONOTHERAPY IN METHOTREXATE-NAÏVE PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS AT 72 WEEKS FROM SELECT-EARLY. Annals of the Rheumatic Diseases. 79. 334–335. 1 indexed citations

Kapetanovic, Meliha C, Mats Andersson, A. Friedman, et al.. (2020). SAT0145 EFFICACY AND SAFETY OF UPADACITINIB MONOTHERAPY IN MTX-NAÏVE PATIENTS WITH EARLY ACTIVE RA RECEIVING TREATMENT WITHIN 3 MONTHS OF DIAGNOSIS: A POST-HOC ANALYSIS OF THE SELECT-EARLY. Annals of the Rheumatic Diseases. 79. 1011–1011. 5 indexed citations

10.

Sornasse, Thierry, et al.. (2020). AB0104 CORRELATION OF PLASMA 14-3-3Η LEVELS WITH DISEASE ACTIVITY MEASURES IN METHOTREXATE-NAÏVE RA PATIENTS TREATED WITH UPADACITINIB MONOTHERAPY IN THE SELECT-EARLY PHASE 3 STUDY. Annals of the Rheumatic Diseases. 79. 1351–1351.

11.

Vollenhoven, Ronald van, Tsutomu Takeuchi, Aileen L. Pangan, et al.. (2019). 059 A phase 3, randomised controlled trial comparing upadacitinib monotherapy to MTX monotherapy in MTX-naïve patients with active rheumatoid arthritis. Lara D. Veeken. 58(Supplement_3). 19 indexed citations

12.

Smolen, Josef S, Stanley Cohen, Paul Emery, et al.. (2019). 060 Upadacitinib as monotherapy: a phase 3 randomised controlled double-blind study in patients with active rheumatoid arthritis and inadequate response to methotrexate. Lara D. Veeken. 58(Supplement_3). 2 indexed citations

13.

Genovese, M. C., Joel M. Kremer, Sheng Zhong, & A. Friedman. (2018). SAT0236 Long-term safety and efficacy of upadacitinib (ABT-494), an oral jak-1 inhibitor in patients with rheumatoid arthritis in an open label extension study. Annals of the Rheumatic Diseases. 77. 979–979. 8 indexed citations

14.

Smolen, J S, Stanley Cohen, Paul Emery, et al.. (2018). OP0035 Upadacitinib as monotherapy: a phase 3 randomised controlled double-blind study in patients with active rheumatoid arthritis and inadequate response to methotrexate. Annals of the Rheumatic Diseases. 77. 67–68. 11 indexed citations

15.

Strand, Vibeke, Janet Pope, Namita Tundia, et al.. (2018). SAT0254 Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs: results from select-next. Annals of the Rheumatic Diseases. 77. 989–990. 2 indexed citations

16.

Kremer, Joel M., Ed Keystone, Paul Emery, et al.. (2016). AB0390 Safety and Efficacy of ABT-494, A Novel Selective JAK1 Inhibitor, in Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance To Anti-TNF Biologic Therapy. Annals of the Rheumatic Diseases. 75. 1038–1039. 7 indexed citations

17.

Garg, Mayur, et al.. (2010). A rapid infusion protocol is safe for total dose iron polymaltose: time for change. Internal Medicine Journal. 41(7). 548–554. 24 indexed citations

18.

Bastian, Holly M., Jeffrey M. Roseman, Gerald McGwin, et al.. (2002). Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus. 11(3). 152–160. 280 indexed citations

19.

Fox, David A., Xiaoyi He, Akira Abe, et al.. (2001). THE T LYMPHOCYTE STRUCTURE CD60 CONTAINS A SIALYLATED CARBOHYDRATE EPITOPE THAT IS EXPRESSED ON BOTH GANGLIOSIDES AND GLYCOPROTEINS. Immunological Investigations. 30(2). 67–85. 20 indexed citations

20.

Friedman, A.. (1999). Party pieces in Joyce's "Dubliners": 436. James Joyce quarterly. 36(3). 471–484. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact